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EDITORIAL

What after BCG Fails in Non-muscle Invasive Bladder
Cancer?
Mohammad Hammad Ather
Department of Surgery, The Aga Khan University Hospital, Karachi, Pakistan

The journey from the pioneering work of Albert Calmette and
Camille Guerrin in the discovery of BCG vaccine for tuberculosis to development of BCG in the management of carcinoma
in situ and high grade non-muscle invasive (NMI) bladder
1,2
cancer is over 100 years old. The story is not only exhilarating
but also full of exciting endeavours from Coleys toxin and
Zbars’ rule to the development of immune checkpoint inhibitors. The concept and development of BCG as an immune
booster in the defence against infectious diseases to a potent
anti-cancer drug, owes to the “magic bullet” concept of Paul
Ehrlich.3
BCG has become one of the most potent immunotherapeutic
agents in the management of high-risk bladder cancer. It is the
treatment of choice for Ta/T1 high-grade (HG) cancer, Ta low
grade (>3cm) as well as for carcinoma in situ (CIS). It is the standard of care for these types of NMI urothelial carcinoma (UC) as
a ﬁrst occurrence and for recurrent BCG naïve cancers. It is also
treatment of choice in cases of recurrent cancer with prior BCG
treatment, not yet a case for radical cystectomy.4 Two major
concerns in NMI urothelial cancer are recurrence and progression of the disease. BCG is highly eﬃcacious in the prevention
of both complications. In ﬁve meta-analyses, it has been
shown that BCG is superior to transurethral resection of
bladder tumor (TURBT) / TURBT + chemotherapy for the
prevention of recurrence.5 Two high quality meta-analyses
have provided level 1a evidence in support of BCG in signiﬁ6
cantly lowering the progression rate. BCG is most eﬀective
when administered in 5-6 cycles of induction with follow-up of
maintenance treatment upto three years. The maintenance
treatment is 3-weekly instillations at 3, 6, 12, 18, 24, 30 and 36
months.
BCG, however, is not an infallible remedy. It is not only associated with signiﬁcant side eﬀects, but there is also signiﬁcant
proportion of patients who fail BCG therapy. The terminology
to describe BCG failure is standardised.
Correspondence to: Dr. Mohammad Hammad Ather,
Department of Surgery, The Aga Khan University
Hospital, Stadium Road, Karachi, Pakistan
E-mail: hammad.ather@aku.edu
.....................................................
Received: July 09, 2021; Revised: September 12, 2021;

Accepted: September 22, 2021
DOI: https://doi.org/10.29271/jcpsp.2022.02.139

BCG refractory tumors are high-grade or CIS NMI cancer
presenting at 3-month or following re-induction or one-cycle of
maintenance and/or if a high-grade tumor appears during maintenance. BCG unresponsive includes T1Ta/HG recurrence
within six months of completion of adequate BCG exposure or if
a patient develops CIS within 12 months of completion of
adequate BCG exposure. BCG relapsing is a high-grade recurrence after complete response on completion of maintenance
therapy. BCG intolerance is the term used for discontinuation of
therapy mandated by signiﬁcant side eﬀects.7
BCG refractory/unresponsive cancers are considered as an
aggressive variant with signiﬁcant potential for metastases.8 The

standard of care in these patients is radical cystectomy (RC).
RC is not only oncologically safe, but it also provides better
cancer-free survival than any other bladder sparing modality.
It may, at times, be an over treatment; albeit in a small proportion of cases. There is overwhelming evidence that delay in
performing cystectomy for BCG refractory cancer can
adversely aﬀect the survival.
Many bladder-sparing regimens are available for patients
unwilling or unﬁt for cystectomy. These include cytotoxic treatment with newer cytotoxic agents, chemotherapy combinations, new drug delivery systems, device instillations, vaccine,
recombinant proteins, photodynamic therapy, oncolytic adenovirus, gene therapy (nadofarageneﬁrodenovac), and immune
checkpoint inhibitors. The last two are of particular interest;
and have received recent FDA approval. However, they should
be considered experimental until wider clinical experience is
reported.
Cancers express various proteins that make them appear
foreign. This results in T cell mediated immune response. In
order to avoid this cascade, tumors often express programme
death ligand (PD L1). This adaptive tumor response turns the
immune system oﬀ. In order to reactivate the immune system,
PD and PDL1 need to be blocked. In a recent phase II trial,
pembrolizumab eﬃcacy was assessed in a study called
Keynote 057. Patients with high-grade papillary UC were
divided into two groups, i.e. with or without concomitant CIS.
Complete response of UC with CIS was the primary end-point;
whereas, CR of any disease, duration of response and safety
and tolerability were the secondary end-points. The CR was just
9
over 40%, mean duration of response was 16.2 months.
In another interesting phase III study, a novel drug delivery
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system, nadofarageneﬁradenovac, for human IFNα2b gene,
was studied. In a non-replicating adenovirus, gene of interest is
inserted, the virus infects the cell and releases DNA that has
signiﬁcant anti-tumor activity. The anti-tumor activity is antiproliferative, TRAIL (tumor necrosis factor apoptosis inducing
ligand) mediated cytotoxicity and anti-angiogenic activity. The
investigators concluded that intravesical nadofarageneﬁradenovec was eﬃcacious. Risk assessment indicates a favourable
beneﬁt: risk ratio, in patients with BCG-unresponsive NMI UC.10
The current European Association of Urology (EAU) guidelines
indicate that standard of care for patients with BCG unresponsive disease is radical cystectomy (strong recommendation);
whereas, evidence-favouring bladder preserving technique is
weak. Close monitoring and early recognition of BCG unresponsiveness is important, as this shows aggressive cancer with
signiﬁcant potential for metastases.
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